Vancouver biotechnology company developing implantable tissue therapeutics through computational design, cell engineering, biomaterials and bioprinting, with diabetes and preclinical adrenal programmes.
Operating context
Aspect’s platform combines computational tissue design, cell and biomaterial processing, AI-powered bioprinting and tissue manufacture. Current pancreatic BTTs use stem-cell islet clusters within immune-protective materials; the public development stage is undisclosed. The separate adrenal programme uses human adrenocortical cells and is preclinical, with supplier-authored animal results. January 2026 Novo terms give Aspect lead development, manufacturing and commercialization responsibility and select islet/hypoimmune technology rights; Novo retains defined later-stage expansion rights. Federal clinical-development funding and planned biomanufacturing capacity do not establish completed facilities or an approved therapy. Study-specific RX1 research methods are distinct from current therapeutic product specifications.
Canadian footprint
Aspect publishes its Canadian operating contact at2131 Manitoba Street, Vancouver BC V5Y0N7. Its active federal entity is ASPECT BIOSYSTEMS LTD.; the January 2026 Novo agreement anchors selected US/Denmark technology and expertise integration to its Canadian platform.
Vancouver, British Columbia is the published city-level context for Aspect Biosystems. It does not imply a street address or exact facility location.
Aspect contributes Canadian tissue-therapeutic research and biomanufacturing development. Compare the specific diabetes or preclinical adrenal programme, cell/material/implant configuration, validated manufacturing and next clinical evidence. Novo rights/workshare and public project support strengthen the development pathway while approved treatment and available capacity remain separate questions.
Interpretation of the public record. Not qualification, endorsement or evidence of buyer interest.
Integrated tissue design, cell engineering, biomaterials and bioprinting for implantable tissue-therapeutic development, including pancreatic islet replacement.
Read technical summary
Integrated tissue design, cell engineering, biomaterials and bioprinting for implantable tissue-therapeutic development, including pancreatic islet replacement.
Evidence of maturity
Current development platform; diabetes stage is publicly undisclosed. Novo’s January 2026 rights/workshare and ISED’s April 2026 support establish development direction. They do not establish clinical efficacy, regulatory approval or completed manufacturing capacity.
Commercial availability
Access through research or pharmaceutical partnering; specify programme, cell/material configuration, rights, validated manufacturing/release methods and clinical/regulatory milestones.
Core features
Computational design followed by cell/biomaterial processing and bioprinted tissue manufacture
Stem-cell islet clusters within immune-protective materials; retrievable pancreatic BTT goal
Novo islet/hypoimmune technology rights with Aspect-led development, manufacture and commercialization
Study-specific printing/material methods and preclinical results remain distinct from product validation
Recorded applications
Metabolic and endocrine cell-therapy development
Domestic biomanufacturing research and capacity development
Bioprinted human adrenocortical-cell tissues under development for primary adrenal insufficiency, supported by supplier-authored animal research.
Read technical summary
Bioprinted human adrenocortical-cell tissues under development for primary adrenal insufficiency, supported by supplier-authored animal research.
Evidence of maturity
Supplier lists Preclinical stage. ENDO2025 supplier-authored abstract and conference-owner context establish animal research presentation, not independent replication, clinical cure or an approved treatment.
Commercial availability
Research/programme partnering route; require the intended cell/material/implant configuration and next clinical/regulatory/manufacturing milestones.
Core features
Human adrenocortical cells in a distinct adrenal BTT programme
Intended response to hormone cues and restoration of adrenal function
Preclinical animal results reported at ENDO2025
Clinical dose, human efficacy and treatment authorization remain separate milestones
Recorded applications
Primary adrenal insufficiency research
Public record
Recent activity
Apr 2, 2026
The April 2, 2026 federal announcement commits CAD 79 million toward Aspect’s CAD 280 million tissue-therapeutic clinical-development project. Targets include maintaining117 and creating283 jobs plus268 student positions. These are planned outputs; the earlier Project Podium remains in progress.
Aspect develops tissue therapeutics through research and pharmaceutical partnerships. Its diabetes stage is publicly undisclosed and its adrenal programme is preclinical; an approved marketed treatment is not established.
Financing and disclosed activity
ISED announced CAD 79 million on April 2, 2026 toward Aspect’s CAD 280 million project; CAD 127 million includes separate Providence support. Earlier federal CAD 49 million and BC CAD 23.75 million concerned the CAD 200 million 2024 project; BC support is not counted again. Aspect announced a closed USD 115 million Series B on January 8, 2025. Novo’s additional January 2026 equity/research funding is undisclosed in amount.
Questions for a first conversation
01
Which next clinical and regulatory milestones apply to the proposed tissue programme, and what completed evidence supports progression?
Diabetes stage is undisclosed, adrenal is preclinical and federal support funds clinical development rather than regulatory approval.
02
Which manufacturing processes and release tests are validated for the intended cells, materials and implant configuration?
Public diagrams omit dose, recipe and validated controls; hiring requirements and animal methods are not completed process validation.
03
Which Aspect and Novo technology, manufacturing and commercialization responsibilities apply to the proposed collaboration?
Aspect leads the January 2026 arrangement; Novo retains defined later-stage expansion rights and future economics.
04
Which funded facility and capacity milestones are complete, and what available capacity can a partner access today?
The 2024 and 2026 projects and job targets are separate planned outputs; earlier BC support must not be counted twice.
Original sources 18 linked records
These records support the organization, its owned capabilities and their reviewed connections. A source count is not a count of independent confirmations.
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
Supports: Profile · commercial status
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
True North Map derives this executive description for Aspect Biosystems from the official identity and technical records together with Innovation, Science and Economic Development Canada's corroborating evidence.
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
Supports: Profile · disclosed financing summary
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
Supports: Bioprinted tissue-therapeutic platform · core features
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
January20 2026 Novo original says Aspect acquired rights to stem-cell-derived islet/hypoimmune engineering technologies,will lead development/manufacturing/commercialisation; Novo has defined later-stage expansion rights,will provide additional equity/research funding,eligible for royalties/milestones on future sales. Amount undisclosed. Selected US/Denmark R&D/manufacturing expertise integrates into Canada-anchored platform; not all global facilities owned or therapy approved.
Supports: Bioprinted tissue-therapeutic platform · core features
Externalacademicauthors withAspectfunding/guidance usedRX1,biosafetycabinet,MIN6clusters orhumanislets,1.5%alginatecore/2%acellularshell,Ca/Bagelation. Studyspecificfibres16mmlong×1.2mmdiameter,about300clusters/islets,fourfibres,40mLmedium/4mLminperfusion. Humanislets notsuitabletherapeutictransplant; these are experimentmethods notcurrentproductspecs orcommercialRX1availability.
True North Map applies the commercial company category to Aspect Biosystems from its documented mandate and source-bounded operating evidence.
ISED April2 2026 announced CAD79million through Strategic Response Fund for Aspect CAD280million project advancing tissue therapeutics and clinical development. CAD127million headline combines this with separate CAD48million Providence Health Care project; it is not all Aspect funding or a payment record.
ISED assigns CAD79million to Aspect's CAD280million project. The headlineCAD127million includes a separate CAD48million Providence Health Care allocation and is not all Aspect funding.
Supports: Profile · current activity
Aspect project targets maintenance of117 and creation of283 jobs for400total and268studentpositions. Facilities/jobs/clinical development are planned outputs, not completed capacity or precise current headcount.2024 CAD49million federal CAD200million ProjectPodium remains in progress.2026release says BC has also supported CAD23.8million; no new2026BC award date is established.
Supports: Profile · current activity
On April 2, 2026, the Government of Canada announced a $79 million contribution toward Aspect's portion of a broader $280 million biomanufacturing project.
ISED April2 2026 announced CAD79million through Strategic Response Fund for Aspect CAD280million project advancing tissue therapeutics and clinical development. CAD127million headline combines this with separate CAD48million Providence Health Care project; it is not all Aspect funding or a payment record.
Supports: Profile · canadian footprint
Aspect Biosystems publishes an operating presence in Vancouver, British Columbia, Canada, and its current public record anchors Bioprinted tissue-therapeutic platform to that Canadian organization.
Supports: Profile · disclosed financing summary
ISED April2 2026 announced CAD79million through Strategic Response Fund for Aspect CAD280million project advancing tissue therapeutics and clinical development. CAD127million headline combines this with separate CAD48million Providence Health Care project; it is not all Aspect funding or a payment record.
Confirm the legal entity and the clinical, regulatory, and manufacturing maturity of each therapeutic program; do not restate curative potential as an achieved outcome. The first conversation should therefore separate current offer, development evidence and accepted operational use.
True North Map derives a first-conversation question about Bioprinted tissue-therapeutic platform configuration and accepted outcomes from the documented maturity boundary.
Supports: Profile · current activity
ISED assigns CAD79million to Aspect's CAD280million project. The headlineCAD127million includes a separate CAD48million Providence Health Care allocation and is not all Aspect funding.
ISED assigns CAD79million to Aspect's CAD280million project. The headlineCAD127million includes a separate CAD48million Providence Health Care allocation and is not all Aspect funding.
Aspect project targets maintenance of117 and creation of283 jobs for400total and268studentpositions. Facilities/jobs/clinical development are planned outputs, not completed capacity or precise current headcount.2024 CAD49million federal CAD200million ProjectPodium remains in progress.2026release says BC has also supported CAD23.8million; no new2026BC award date is established.
ISED April2 2026 announced CAD79million through Strategic Response Fund for Aspect CAD280million project advancing tissue therapeutics and clinical development. CAD127million headline combines this with separate CAD48million Providence Health Care project; it is not all Aspect funding or a payment record.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
Aspect project targets maintenance of117 and creation of283 jobs for400total and268studentpositions. Facilities/jobs/clinical development are planned outputs, not completed capacity or precise current headcount.2024 CAD49million federal CAD200million ProjectPodium remains in progress.2026release says BC has also supported CAD23.8million; no new2026BC award date is established.
Supports: Profile · disclosed financing summary
ISED assigns CAD79million to Aspect's CAD280million project. The headlineCAD127million includes a separate CAD48million Providence Health Care allocation and is not all Aspect funding.
Supports: Profile · current activity as of
Innovation, Science and Economic Development Canada's dated record anchors this activity to 2026-04-02.
Supports: Profile · organization categories
True North Map applies the dual use category to Aspect Biosystems from its documented mandate and source-bounded operating evidence.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
ISED assigns CAD79million to Aspect's CAD280million project. The headlineCAD127million includes a separate CAD48million Providence Health Care allocation and is not all Aspect funding.
Supports: Profile · dual use posture
Bioprinted tissue-therapeutic platform has documented civilian or industrial applications and a bounded potential relevance to Canadian defence, security or strategic-infrastructure needs.
Aspect project targets maintenance of117 and creation of283 jobs for400total and268studentpositions. Facilities/jobs/clinical development are planned outputs, not completed capacity or precise current headcount.2024 CAD49million federal CAD200million ProjectPodium remains in progress.2026release says BC has also supported CAD23.8million; no new2026BC award date is established.
Supports: Profile · operating context
Aspect project targets maintenance of117 and creation of283 jobs for400total and268studentpositions. Facilities/jobs/clinical development are planned outputs, not completed capacity or precise current headcount.2024 CAD49million federal CAD200million ProjectPodium remains in progress.2026release says BC has also supported CAD23.8million; no new2026BC award date is established.
ISED April2 2026 announced CAD79million through Strategic Response Fund for Aspect CAD280million project advancing tissue therapeutics and clinical development. CAD127million headline combines this with separate CAD48million Providence Health Care project; it is not all Aspect funding or a payment record.
Aspect project targets maintenance of117 and creation of283 jobs for400total and268studentpositions. Facilities/jobs/clinical development are planned outputs, not completed capacity or precise current headcount.2024 CAD49million federal CAD200million ProjectPodium remains in progress.2026release says BC has also supported CAD23.8million; no new2026BC award date is established.
Aspect project targets maintenance of117 and creation of283 jobs for400total and268studentpositions. Facilities/jobs/clinical development are planned outputs, not completed capacity or precise current headcount.2024 CAD49million federal CAD200million ProjectPodium remains in progress.2026release says BC has also supported CAD23.8million; no new2026BC award date is established.
ISED assigns CAD79million to Aspect's CAD280million project. The headlineCAD127million includes a separate CAD48million Providence Health Care allocation and is not all Aspect funding.
ISED assigns CAD79million to Aspect's CAD280million project. The headlineCAD127million includes a separate CAD48million Providence Health Care allocation and is not all Aspect funding.
Supports: Profile · disclosed financing summary
Aspect project targets maintenance of117 and creation of283 jobs for400total and268studentpositions. Facilities/jobs/clinical development are planned outputs, not completed capacity or precise current headcount.2024 CAD49million federal CAD200million ProjectPodium remains in progress.2026release says BC has also supported CAD23.8million; no new2026BC award date is established.
Supports: Profile · current activity
ISED April2 2026 announced CAD79million through Strategic Response Fund for Aspect CAD280million project advancing tissue therapeutics and clinical development. CAD127million headline combines this with separate CAD48million Providence Health Care project; it is not all Aspect funding or a payment record.
Innovation, Science and Economic Development Canada's public evidence confirms a company-specific project, award, program or operating context, while configuration-specific acceptance and scale remain bounded by the reviewer warning.
Aspect project targets maintenance of117 and creation of283 jobs for400total and268studentpositions. Facilities/jobs/clinical development are planned outputs, not completed capacity or precise current headcount.2024 CAD49million federal CAD200million ProjectPodium remains in progress.2026release says BC has also supported CAD23.8million; no new2026BC award date is established.
ISED April2 2026 announced CAD79million through Strategic Response Fund for Aspect CAD280million project advancing tissue therapeutics and clinical development. CAD127million headline combines this with separate CAD48million Providence Health Care project; it is not all Aspect funding or a payment record.
Current supplier lists2131ManitobaStreetVancouverBCV5Y0N7,+16042630502,info@aspectbiosystems.com and BD/Partnering inquiry form; media@aspectbiosystems.com is separately media-only. Public business contact,not private outreach authorization.
Current supplier lists2131ManitobaStreetVancouverBCV5Y0N7,+16042630502,info@aspectbiosystems.com and BD/Partnering inquiry form; media@aspectbiosystems.com is separately media-only. Public business contact,not private outreach authorization.
Supports: Profile · website url
https://www.aspectbiosystems.com/ is the canonical official website used by Aspect Biosystems.
Current supplier lists2131ManitobaStreetVancouverBCV5Y0N7,+16042630502,info@aspectbiosystems.com and BD/Partnering inquiry form; media@aspectbiosystems.com is separately media-only. Public business contact,not private outreach authorization.
Supports: Profile · primary location.countrycode
Aspect Biosystems publishes a Canadian operating presence, represented by country code CA.
Supports: Profile · canadian footprint
Current supplier lists2131ManitobaStreetVancouverBCV5Y0N7,+16042630502,info@aspectbiosystems.com and BD/Partnering inquiry form; media@aspectbiosystems.com is separately media-only. Public business contact,not private outreach authorization.
Supports: Profile · entity kind
True North Map classifies Aspect Biosystems as a company from its documented legal or institutional role.
Supports: Profile · primary location.longitude
True North Map uses the Vancouver city centroid longitude -123.1207 for a city-level map location.
Current supplier lists2131ManitobaStreetVancouverBCV5Y0N7,+16042630502,info@aspectbiosystems.com and BD/Partnering inquiry form; media@aspectbiosystems.com is separately media-only. Public business contact,not private outreach authorization.
Current supplier lists2131ManitobaStreetVancouverBCV5Y0N7,+16042630502,info@aspectbiosystems.com and BD/Partnering inquiry form; media@aspectbiosystems.com is separately media-only. Public business contact,not private outreach authorization.
Current supplier lists2131ManitobaStreetVancouverBCV5Y0N7,+16042630502,info@aspectbiosystems.com and BD/Partnering inquiry form; media@aspectbiosystems.com is separately media-only. Public business contact,not private outreach authorization.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Profile · description
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Profile · commercial status
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Profile · operating context
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Profile · profileData.portfolioScope
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Profile · description
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supports: Profile · operating context
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supports: Profile · profileData.portfolioScope
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Profile · commercial status
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supports: Bioprinted tissue-therapeutic platform · display lead
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supports: Bioprinted tissue-therapeutic platform · core features
Supplier describes retrievable pancreatic BTTs containing allogeneic stem-cell islet clusters within immune-protective materials, intended to sense glucose and release insulin without immune suppression. Current diabetes development stage is explicitly Undisclosed; intended functional cure is not attained clinical efficacy.
Supports: Preclinical adrenal tissue therapeutics · core features
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Preclinical adrenal tissue therapeutics · display lead
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Preclinical adrenal tissue therapeutics · name
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Preclinical adrenal tissue therapeutics · core features
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Preclinical adrenal tissue therapeutics · core features
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supports: Preclinical adrenal tissue therapeutics · capability type
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
Supplier lists human adrenocortical-cell BTTs for primary adrenal insufficiency at Preclinical stage. Intended responses to hormone cues and natural daily rhythms are development goals, not an approved off-the-shelf therapy.
BC2023–2024 reportp5 says CAD23.75million announced for Aspect full-stack tissue therapeutic facility. Aspect July10 2024 original combined CAD72.75million federal/BC toward CAD200million multiyearproject. Rounded23.8million restated inApril2026 is not newlyawarded2026BCfunding or evidence completedfacility.
Supports: Profile · disclosed financing summary
BC2023–2024 reportp5 says CAD23.75million announced for Aspect full-stack tissue therapeutic facility. Aspect July10 2024 original combined CAD72.75million federal/BC toward CAD200million multiyearproject. Rounded23.8million restated inApril2026 is not newlyawarded2026BCfunding or evidence completedfacility.
BC2023–2024 reportp5 says CAD23.75million announced for Aspect full-stack tissue therapeutic facility. Aspect July10 2024 original combined CAD72.75million federal/BC toward CAD200million multiyearproject. Rounded23.8million restated inApril2026 is not newlyawarded2026BCfunding or evidence completedfacility.
BC2023–2024 reportp5 says CAD23.75million announced for Aspect full-stack tissue therapeutic facility. Aspect July10 2024 original combined CAD72.75million federal/BC toward CAD200million multiyearproject. Rounded23.8million restated inApril2026 is not newlyawarded2026BCfunding or evidence completedfacility.
BC2023–2024 reportp5 says CAD23.75million announced for Aspect full-stack tissue therapeutic facility. Aspect July10 2024 original combined CAD72.75million federal/BC toward CAD200million multiyearproject. Rounded23.8million restated inApril2026 is not newlyawarded2026BCfunding or evidence completedfacility.
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supports: Profile · commercial status
Aspect Biosystems currently presents Bioprinted tissue-therapeutic platform as part of its public commercial offering.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supports: Profile · operating context
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supports: Profile · operating context
Aspect Biosystems operates from Vancouver, British Columbia, with a public mandate centred on Bioprinted tissue-therapeutic platform; public sources do not establish every customer, configuration or operational outcome.
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supports: Profile · profileData.portfolioScope
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supports: Profile · profileData.portfolioScope
Aspect Biosystems's documented portfolio in this dossier is bounded to Bioprinted tissue-therapeutic platform and the source-backed functions listed below.
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supports: Bioprinted tissue-therapeutic platform · core features
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Aspect's full-stack platform is designed to manufacture biologically functional, implantable tissues and to support tissue design and therapeutic development. Clinical efficacy and regulatory approval are not established by the sources reviewed.
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
True North Map maps Bioprinted tissue-therapeutic platform to advanced manufacturing and integration from its documented technology functions.
Supports: Bioprinted tissue-therapeutic platform · core features
AI-assisted bioprinting and computational tissue design
Supports: Bioprinted tissue-therapeutic platform · capability type
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Domestic biomanufacturing and health-system resilience
Supports: Bioprinted tissue-therapeutic platform · display lead
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supports: Bioprinted tissue-therapeutic platform · core features
Integrated cells, biomaterials, and hypoimmune engineering
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supports: Bioprinted tissue-therapeutic platform · name
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supports: Bioprinted tissue-therapeutic platform · name
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Supports: Bioprinted tissue-therapeutic platform · capability type
Supplier platform computational tissue design→cell/biomaterial processing→AI-powered bioprinting/tissue manufacturing→implantation/functional-cure goal. Diagram labels therapeutic-cell core,Shell1,Shell2. No public dose,recipe,dimensions or validated AI-control parameters; intended biological functionality/immune protection is not proven current clinical performance.
Aspect receives expanded rights to Novo cell technologies and leads development, manufacturing and commercialization, with additional undisclosed equity/research support and defined future Novo rights.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
Aspect receives expanded rights to Novo cell technologies and leads development, manufacturing and commercialization, with additional undisclosed equity/research support and defined future Novo rights.
Supports: Profile · operating context
Aspect receives expanded rights to Novo cell technologies and leads development, manufacturing and commercialization, with additional undisclosed equity/research support and defined future Novo rights.
NRC agreement997886 records CAD841683 Contribution September1 2022–October31 2023 to Aspect Biosystems Ltd. BN830167839. Purpose was pancreatic regulatory/development milestones toward final IND-enabling studies and demonstrating liver tissue efficacy in multiple diseases. Intended milestone is not proof achieved; historical liver research does not establish a current separately offered liver therapy. Additional amended value166500 is not added again to the displayed agreement without reconciliation.
Supports: Profile · legal name
NRC agreement997886 records CAD841683 Contribution September1 2022–October31 2023 to Aspect Biosystems Ltd. BN830167839. Purpose was pancreatic regulatory/development milestones toward final IND-enabling studies and demonstrating liver tissue efficacy in multiple diseases. Intended milestone is not proof achieved; historical liver research does not establish a current separately offered liver therapy. Additional amended value166500 is not added again to the displayed agreement without reconciliation.
ASPECT BIOSYSTEMS LTD. is active corporation1649671-7, a November4 2024 amalgamation of predecessor Aspect1199072-1 and16488013CanadaInc. Predecessor870153-9 incorporated November19 2013 and amalgamated April3 2020. The2024 date is not founding. Registry is non-distributing with more than50 shareholders; ultimate control/current capitalization remains unknown. 2025 return filed,2026 not yet due; hidden overdue template text is not the live status.
Supports: Profile · legal name
ASPECT BIOSYSTEMS LTD. is active corporation1649671-7, a November4 2024 amalgamation of predecessor Aspect1199072-1 and16488013CanadaInc. Predecessor870153-9 incorporated November19 2013 and amalgamated April3 2020. The2024 date is not founding. Registry is non-distributing with more than50 shareholders; ultimate control/current capitalization remains unknown. 2025 return filed,2026 not yet due; hidden overdue template text is not the live status.
Supports: Profile · founded year
ASPECT BIOSYSTEMS LTD. is active corporation1649671-7, a November4 2024 amalgamation of predecessor Aspect1199072-1 and16488013CanadaInc. Predecessor870153-9 incorporated November19 2013 and amalgamated April3 2020. The2024 date is not founding. Registry is non-distributing with more than50 shareholders; ultimate control/current capitalization remains unknown. 2025 return filed,2026 not yet due; hidden overdue template text is not the live status.
InBC original portfolio lists Aspect Established2013 and YearInvested2024. Corroborates companyorigin rather than treating current2024amalgamation asfounding; does not disclose equitypercentage or totalfunding.
Aspect January8 2025 original says closedUS115million SeriesB ledbyDimension withNovo/InBCinvestors,intended toadvanceprogrammestowardclinic. Closedfinancing is distinct from undisclosed futureJanuary2026Novo support; earlier pipeline references are not currentofferproof.
Supplier describes AI-powered bioprinting, computational design, therapeutic cells and biomaterials for allogeneic implantable tissue therapeutics targeting metabolic/endocrine disease. This is platform and development positioning, not a clinically approved cure or military product.
Supports: Profile · executive relevance summary
Source location: executiveRelevanceSummary
Aspect describes a therapeutic platform combining bioprinting, cell engineering and biomaterials to develop implantable tissue treatments; this does not establish approved therapy.
Supports: Profile · operating context
Aspect describes a therapeutic platform combining bioprinting, cell engineering and biomaterials to develop implantable tissue treatments; this does not establish approved therapy.
Aspect combines bioprinting, computational design, therapeutic cells and biomaterials to develop implantable allogeneic tissue therapeutics. Its stated therapeutic scope targets replacement, repair or supplementation of biological functions for metabolic and endocrine disease. The commercial pathway is therapeutic development with pharma/biotech partners, not an off-the-shelf approved treatment.
Supports: Bioprinted tissue-therapeutic platform · name
Aspect combines bioprinting, computational design, therapeutic cells and biomaterials to develop implantable allogeneic tissue therapeutics. Its stated therapeutic scope targets replacement, repair or supplementation of biological functions for metabolic and endocrine disease. The commercial pathway is therapeutic development with pharma/biotech partners, not an off-the-shelf approved treatment.
Aspect combines bioprinting, computational design, therapeutic cells and biomaterials to develop implantable allogeneic tissue therapeutics. Its stated therapeutic scope targets replacement, repair or supplementation of biological functions for metabolic and endocrine disease. The commercial pathway is therapeutic development with pharma/biotech partners, not an off-the-shelf approved treatment.
Aspect combines bioprinting, computational design, therapeutic cells and biomaterials to develop implantable allogeneic tissue therapeutics. Its stated therapeutic scope targets replacement, repair or supplementation of biological functions for metabolic and endocrine disease. The commercial pathway is therapeutic development with pharma/biotech partners, not an off-the-shelf approved treatment.
Aspect combines bioprinting, computational design, therapeutic cells and biomaterials to develop implantable allogeneic tissue therapeutics. Its stated therapeutic scope targets replacement, repair or supplementation of biological functions for metabolic and endocrine disease. The commercial pathway is therapeutic development with pharma/biotech partners, not an off-the-shelf approved treatment.
Supports: Bioprinted tissue-therapeutic platform · capability type
Aspect combines bioprinting, computational design, therapeutic cells and biomaterials to develop implantable allogeneic tissue therapeutics. Its stated therapeutic scope targets replacement, repair or supplementation of biological functions for metabolic and endocrine disease. The commercial pathway is therapeutic development with pharma/biotech partners, not an off-the-shelf approved treatment.
Aspect combines bioprinting, computational design, therapeutic cells and biomaterials to develop implantable allogeneic tissue therapeutics. Its stated therapeutic scope targets replacement, repair or supplementation of biological functions for metabolic and endocrine disease. The commercial pathway is therapeutic development with pharma/biotech partners, not an off-the-shelf approved treatment.
Supports: Bioprinted tissue-therapeutic platform · core features
Aspect combines bioprinting, computational design, therapeutic cells and biomaterials to develop implantable allogeneic tissue therapeutics. Its stated therapeutic scope targets replacement, repair or supplementation of biological functions for metabolic and endocrine disease. The commercial pathway is therapeutic development with pharma/biotech partners, not an off-the-shelf approved treatment.
Aspect combines bioprinting, computational design, therapeutic cells and biomaterials to develop implantable allogeneic tissue therapeutics. Its stated therapeutic scope targets replacement, repair or supplementation of biological functions for metabolic and endocrine disease. The commercial pathway is therapeutic development with pharma/biotech partners, not an off-the-shelf approved treatment.
Supports: Bioprinted tissue-therapeutic platform · core features
Aspect combines bioprinting, computational design, therapeutic cells and biomaterials to develop implantable allogeneic tissue therapeutics. Its stated therapeutic scope targets replacement, repair or supplementation of biological functions for metabolic and endocrine disease. The commercial pathway is therapeutic development with pharma/biotech partners, not an off-the-shelf approved treatment.
Aspect combines bioprinting, computational design, therapeutic cells and biomaterials to develop implantable allogeneic tissue therapeutics. Its stated therapeutic scope targets replacement, repair or supplementation of biological functions for metabolic and endocrine disease. The commercial pathway is therapeutic development with pharma/biotech partners, not an off-the-shelf approved treatment.
Aspect describes a January 2026 partnership phase integrating Novo Nordisk stem-cell-derived islet and hypoimmune-cell engineering technologies; clinical efficacy and approval are not established by that agreement. The Novo Nordisk collaboration began in 2023 and supports development of cellular medicines; integration of technology is distinct from delivery of an approved therapy.
Aspect describes a January 2026 partnership phase integrating Novo Nordisk stem-cell-derived islet and hypoimmune-cell engineering technologies; clinical efficacy and approval are not established by that agreement. The Novo Nordisk collaboration began in 2023 and supports development of cellular medicines; integration of technology is distinct from delivery of an approved therapy.
Supports: Bioprinted tissue-therapeutic platform · core features
Aspect describes a January 2026 partnership phase integrating Novo Nordisk stem-cell-derived islet and hypoimmune-cell engineering technologies; clinical efficacy and approval are not established by that agreement. The Novo Nordisk collaboration began in 2023 and supports development of cellular medicines; integration of technology is distinct from delivery of an approved therapy.
Conference owner reports Aspect researcher preclinical adrenal BTT presentation for primary adrenal insufficiency. This is corroboration of conference/research context, not independent replication of supplier-authored experimental results.
Continue through related organizations, reviewed mission and Defence need connections, programme pathways, and explicitly linked intelligence. Similarity results describe shared areas of work, not partnerships or endorsements.
Organizations
Profiles that provide the strongest reviewed or discovery-led continuation.
